← All trials
NCT06235216
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 13, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jan 31, 2024
- Last posted
- Nov 1, 2024
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)Lead sponsor
- Gilead SciencesCollaborator
- MFAR Clinical ResearchCollaborator
- Vall d'Hebron Institute of Research, Galatea ClinicOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.